<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074526</url>
  </required_header>
  <id_info>
    <org_study_id>OFORT003</org_study_id>
    <nct_id>NCT03074526</nct_id>
  </id_info>
  <brief_title>Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Prospective, Double Blinded Randomized Multi-Center Controlled Trial Evaluating the 2 Different Doses of Lyophilized Amniotic Fluid Compared to a Saline Placebo Injection in the Treatment of Subjects With Osteoarthritic (OA) Knee Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of Lyophilized amniotic fluid as compared to the Saline Injection,
      placebo control in the treatment of moderate osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo
      and 4ml 2x). The estimated enrollment period is 6 months. Each subject will receive 1
      injection and be evaluated for efficacy and safety during a 6 month observation period. The
      study is expected to be completed within 12 months, inclusive of enrollment and follow-up for
      all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo and 4ml 2x).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Pain</measure>
    <time_frame>3 month</time_frame>
    <description>The proportion of subjects who experience at least 20% improvement over baseline in Visual Analog Scale for Pain at 3 months in the Lyophilized amniotic fluid Injectable versus placebo-treated group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>3 months</time_frame>
    <description>subjects who experience a level of improvement in function as assessed by range of motion at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score</measure>
    <time_frame>4weeks, 6weeks, 3 months, 16 weeks, 6 months</time_frame>
    <description>measurement to assess the patient's opinion about their knee and associated problems by looking at pain, functions of daily living, function in sports and recreation, knee related quality of life and other symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 Health Health Survey</measure>
    <time_frame>4weeks, 6weeks, 3 months, 16 weeks, 6 months</time_frame>
    <description>patient-reported survey assessing patient health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of Daily Living Questionnaire</measure>
    <time_frame>4weeks, 6weeks, 3 months, 16 weeks, 6 months</time_frame>
    <description>Changes in the subject's physical activity level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>4mL amniotic fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amniotic Fluid: 4mL dose of amniotic fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mL2x amniotic fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amniotic Fluid: 4mL 2x dose of amniotic fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mL Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic Fluid</intervention_name>
    <description>Amniotic Fluid</description>
    <arm_group_label>4mL amniotic fluid</arm_group_label>
    <arm_group_label>4mL2x amniotic fluid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline Placebo</description>
    <arm_group_label>4mL Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 30 years or older.

          2. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren
             Lawrence grading scale.

          3. Subject is willing and able provide informed consent and participate in all procedures
             and follow-up evaluations necessary to complete the study.

          4. Subject must have a VAS pain scale greater than 30.

        Exclusion Criteria:

          1. Subject has active infection at the injection site.

          2. Subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any
             other auto-immune disorders that could be the cause of their knee pain.

          3. BMI greater than 45 kg/m2

          4. Subject has received an intra-articular hyaluronic acid (HA) injection for the
             treatment of OA of the target knee within 12 weeks prior to screening.

          5. Subject has received a steroid or platelet rich plasma (PRP) injection for the
             treatment of OA of the target knee within 12 weeks prior to screening.

          6. Subject has had major surgery or arthroscopy in the target knee within 26 weeks of
             treatment or plans to have surgery in the target knee within 180 days of treatment.

          7. Subject is pregnant or plans to become pregnant within 180 days of treatment.

          8. Subject has used an investigational drug, device or biologic within 12 weeks prior to
             treatment.

          9. Subject has any significant medical condition that, in the opinion of the
             Investigator, would interfere with protocol evaluation and participation.

         10. Subject has a history of immunosuppressive or chemotherapy in the last 5 years

         11. Subject has autoimmune disease or a known history of having Acquired Immunodeficiency
             Syndromes (AIDS) or HIV

         12. Subject has had prior radiation at the site

         13. Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin)

         14. New diagnosis of gout in the past 6 month

         15. Subject has a diagnosis of osteoarthritis (OA) defined as Grade 4 on the Kellgren
             Lawrence grading scale.

         16. Subject has a diagnosis of Osteonecrosis of the knee.

         17. Subject has had a total knee replacement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Fetterolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stan Harris</last_name>
    <phone>770-651-9223</phone>
    <email>sharris@mimedx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary K Pynes</last_name>
    <email>mpynes@mimedx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Research Associates, Inc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weil Foot, Ankle and Orthopedic Institute</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sheinkop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hinsdale Orthopaedic Associates</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

